NRx FDA Review: Preservative-Free Ketamine Moves Forward

What Happened

NRx Pharmaceuticals signaled meaningful progress in April 2026 on its FDA review process for a preservative-free ketamine formulation, according to a report from CityBiz. While the company has not announced a final approval date, the disclosure that its application is advancing through the FDA's review pipeline is a notable development for a segment of the ketamine market that has long operated in a regulatory gray zone — compounded, off-label, and largely outside the reach of standardized pharmaceutical manufacturing oversight.

The application centers on a preservative-free formulation of ketamine intended for clinical use. This is distinct from both the compounded ketamine widely used by infusion clinics today and from esketamine (Spravato), the FDA-approved nasal spray that contains only the S-enantiomer of ketamine. A successful NRx application would introduce a new commercially manufactured, preservative-free racemic ketamine product into a market that currently lacks one.

Why the Preservative Question Actually Matters

Most people investigating low-dose ketamine therapy — whether for depression, chronic pain, or other off-label applications — encounter ketamine as a compounded product sourced from a 503A or 503B pharmacy. These compounded preparations can be made preservative-free, and many clinics specifically request them for IV infusion use. But the broader market reality is messier: many standard multi-dose ketamine vials used in clinical settings contain preservatives such as benzethonium chloride.

Preservatives serve a legitimate purpose in multi-dose vials — they prevent microbial contamination when a vial is punctured repeatedly. But they come with tradeoffs that matter in a low-dose ketamine context:

• Neurotoxicity concern at higher concentrations: Benzethonium chloride and similar agents have raised questions in the research literature about neurotoxicity, particularly in contexts involving intrathecal (spinal) or epidural administration. For standard IV ketamine infusions, preservative exposure is generally considered low-risk, but the concern has informed clinical preferences toward preservative-free formulations nonetheless.
• Repeated-infusion accumulation: Patients undergoing ketamine for treatment-resistant depression often receive multiple infusions across a short induction period — commonly six infusions over two to three weeks — followed by periodic maintenance sessions. Over time, even small exposures accumulate, and clinicians managing long-term ketamine programs have increasingly preferred preservative-free formulations as a precautionary measure.
• Intranasal and sublingual routes: Low-dose ketamine is frequently administered via intranasal or sublingual routes, particularly in at-home maintenance protocols. Preservatives that are well-tolerated in an IV context can cause mucosal irritation when applied to nasal or oral tissue. Preservative-free options are strongly preferred for these delivery routes.
• Regulatory signal about quality standardization: FDA approval of a commercially manufactured preservative-free ketamine formulation would represent a higher bar of manufacturing consistency than compounded products typically meet. For clinics and patients, that can translate to more predictable drug concentration and sterility assurance.

The clinical significance of preservative exposure in standard IV ketamine infusion is genuinely debated — most practitioners consider it a minor concern for otherwise healthy adults receiving occasional infusions. But for patients on long-term low-dose protocols, the formulation question becomes more clinically meaningful.

The Regulatory Landscape This Fits Into

The timing of NRx's progress disclosure is worth contextualizing. The FDA's relationship with ketamine has been in flux for several years. Spravato (esketamine) received approval in 2019 for treatment-resistant depression and later for major depressive disorder with suicidal ideation — but its REMS program, which requires in-office administration and monitoring for two hours post-dose, has limited adoption. Many patients and clinicians have found it cumbersome compared to IV ketamine infusions, which, despite lacking FDA approval for psychiatric use, have become a well-established off-label practice.

Meanwhile, the FDA has intermittently applied pressure to compounding pharmacies producing ketamine — particularly regarding telehealth-prescribing companies that dispensed at-home ketamine kits with minimal oversight. A 2023 FDA advisory and subsequent enforcement actions against certain compounders put the at-home ketamine market on notice. In that environment, a commercially approved preservative-free ketamine product could provide both patients and clinicians a cleaner regulatory pathway — one that doesn't depend on the compounding exemptions that regulators have shown increasing interest in scrutinizing.

If NRx's application succeeds, it would not eliminate compounded ketamine from the market — compounders can still serve clinical needs that commercial products don't meet, and the pricing dynamics of a commercial pharmaceutical versus a compounded preparation will matter considerably. But it would add a commercially manufactured option that carries FDA manufacturing standards, labeling requirements, and potentially clearer prescribing guidance.

It's important to note that FDA review progress does not guarantee approval. NRx has not specified a timeline, and pharmaceutical applications of this kind can encounter additional requests for information, safety reviews, or formulation data before a final decision is rendered. The signal here is directional, not a done deal.

The Broader Implication for Low-Dose Ketamine's Legitimacy

One underappreciated dimension of this regulatory development is what it signals about the direction of ketamine's clinical future. NRx filing a serious FDA application for a preservative-free formulation reflects an industry calculation that ketamine, in some form, has a commercial future beyond the current off-label infusion market. Investment in FDA-grade manufacturing and regulatory process is expensive and time-consuming — companies pursue it when they expect the market will reward it.

For patients and practitioners who have watched ketamine therapy occupy an uncertain regulatory position for years — valuable and evidence-supported in clinical practice, but underpinned by off-label prescribing and compounding arrangements that have faced periodic regulatory challenge — the gradual formalization of ketamine's commercial and regulatory status is relevant. It points toward a future where ketamine is more tightly integrated into standard pharmaceutical frameworks, with the benefits (manufacturing consistency, clearer labeling, insurance coverage pathways) and constraints (REMS-style monitoring requirements, cost structures) that typically accompany that integration.

That future isn't here yet. But NRx's application progress is one more data point suggesting it's coming. For people making decisions now about how to structure long-term ketamine maintenance — whether through infusion clinics, compounding pharmacies, or emerging commercial options — staying informed about the regulatory environment is part of making sound, durable choices about care.